150 Participants Needed

Coin2Dose for Type 1 Diabetes

(Coin2Dose Trial)

Recruiting at 1 trial location
KM
SR
Overseen BySusana R Patton, PhD
Age: < 18
Sex: Any
Trial Phase: Academic
Sponsor: Nemours Children's Clinic
Must be taking: Insulin
No Placebo GroupAll trial participants will receive the active study treatment (no placebo)

What You Need to Know Before You Apply

What is the purpose of this trial?

This trial tests if rewards and reminders can help teenagers with type 1 diabetes take their insulin more regularly. The goal is to improve their health by making it easier for them to manage their condition.

Do I have to stop taking my current medications for the trial?

The trial protocol does not specify whether you need to stop taking your current medications. However, since the trial involves using an insulin pump, you will likely continue using it as part of your diabetes management.

Will I have to stop taking my current medications?

The trial information does not specify whether you need to stop taking your current medications. However, since the trial involves adolescents using an insulin pump, it seems likely that participants will continue their current insulin regimen.

What safety data is available for Coin2Dose treatment in Type 1 Diabetes?

The provided research does not directly mention safety data for Coin2Dose or Cash-Only INcentives To promote insulin DOSE engagement. The studies focus on insulin analogs, device safety, glucagon use, and hypoglycemia management, but do not specifically address Coin2Dose. Therefore, no specific safety data for Coin2Dose is available in the provided research.12345

Is Coin2Dose a promising treatment for Type 1 Diabetes?

Yes, Coin2Dose is a promising treatment for Type 1 Diabetes because it uses financial rewards to encourage people to manage their diabetes better. Studies show that offering money can motivate patients to monitor their blood sugar levels more frequently, which is important for managing diabetes effectively.678910

How is the Coin2Dose treatment different from other treatments for type 1 diabetes?

Coin2Dose is unique because it uses financial incentives to encourage people with type 1 diabetes to regularly take their insulin and manage their blood sugar levels, unlike traditional treatments that focus solely on medication and lifestyle changes.678910

What data supports the idea that Coin2Dose for Type 1 Diabetes is an effective treatment?

The available research shows that using financial incentives, like those in Coin2Dose, can help improve self-monitoring of blood glucose in adolescents with type 1 diabetes. A study found that monetary rewards increased the frequency of checking blood sugar levels, which is important for managing diabetes effectively. This suggests that Coin2Dose can be an effective treatment by encouraging better diabetes management behaviors.6791011

What data supports the effectiveness of the Coin2Dose treatment for Type 1 Diabetes?

Research shows that using financial incentives can help people with diabetes improve their self-management behaviors, like monitoring blood sugar levels more regularly. This suggests that the Coin2Dose treatment, which uses cash incentives, might encourage better insulin use in people with Type 1 Diabetes.6791011

Are You a Good Fit for This Trial?

This trial is for English-speaking teens aged 11-17 with Type 1 Diabetes who use an insulin pump but have a low daily BOLUS score, indicating they're not using enough insulin. They must be diagnosed for at least 6 months. Teens with allergies to CGM adhesives or other chronic conditions like renal disease can't join.

Inclusion Criteria

I have been diagnosed with type 1 diabetes for at least 6 months.
Adolescents who have a daily BOLUS score below 2.5
I use an insulin pump for my type 1 diabetes.
See 1 more

Exclusion Criteria

I am a teenager who does not use an insulin pump.
I am allergic to the adhesive used for continuous glucose monitoring.
I am a teenager with a long-term health condition like kidney disease.

Timeline for a Trial Participant

Screening

Participants are screened for eligibility to participate in the trial

2-4 weeks

Treatment

Participants receive the Coin2Dose intervention or standard care for 12 weeks

12 weeks
Telehealth sessions

Follow-up

Participants are monitored for safety and effectiveness after treatment

12 weeks

What Are the Treatments Tested in This Trial?

Interventions

  • Coin2Dose
Trial Overview The Coin2Dose program uses behavioral economics incentives to encourage teens with Type 1 Diabetes to increase their daily insulin BOLUS usage. The study will assess if this approach is practical, acceptable, and effective in improving diabetes management.
How Is the Trial Designed?
2Treatment groups
Experimental Treatment
Active Control
Group I: Coin2DoseExperimental Treatment1 Intervention
BEI intervention that also combines automated text message reminders to dose for insulin; will test Contingent and Non-Contingent BEI
Group II: Standard Care ControlActive Control1 Intervention
Standard care control group; will not receive automated text message reminders to dose for insulin nor BEI for daily BOLUS scores

Find a Clinic Near You

Who Is Running the Clinical Trial?

Nemours Children's Clinic

Lead Sponsor

Trials
128
Recruited
18,000+

Published Research Related to This Trial

A qualitative study involving 12 patients with diabetes revealed that 83% were interested in using financial incentives to enhance their self-management of the condition.
Incentives can help patients during the initial learning phase of developing healthy habits and also acknowledge their efforts during stable management phases, but careful planning is needed to prevent a decrease in intrinsic motivation.
An exploration of attitudes toward the use of patient incentives to support diabetes self-management.Blondon, K., Klasnja, P., Coleman, K., et al.[2018]
A national survey of 153 adults with diabetes revealed that 96% were interested in financial incentives to improve their self-management, indicating a strong willingness to use monetary rewards for behavior change.
The study found that the perceived challenge of diabetes self-management tasks influenced the likelihood of using financial incentives, with participants expecting relatively modest amounts of money to motivate significant weight loss (e.g., $258 for a 5 lb loss).
Patient attitudes about financial incentives for diabetes self-management: A survey.Blondon, KS.[2020]
A monetary-based reinforcement intervention significantly increased the frequency of self-monitoring of blood glucose (SMBG) among 60 youth with poorly controlled type 1 diabetes, with the proportion of days completing ≥4 SMBG rising from 14.6% at baseline to 64.4% at 6 weeks.
While the intervention led to a decrease in average A1c levels from 9.5% to 9.0% during the reinforcement period, these improvements in metabolic control were not sustained after the withdrawal of monetary rewards, indicating a need for ongoing support to maintain benefits.
Glucose management for rewards: A randomized trial to improve glucose monitoring and associated self-management behaviors in adolescents with type 1 diabetes.Wagner, JA., Petry, NM., Weyman, K., et al.[2020]

Citations

An exploration of attitudes toward the use of patient incentives to support diabetes self-management. [2018]
Patient attitudes about financial incentives for diabetes self-management: A survey. [2020]
Glucose management for rewards: A randomized trial to improve glucose monitoring and associated self-management behaviors in adolescents with type 1 diabetes. [2020]
Cost-effectiveness of financial incentives to improve glycemic control in adults with diabetes: A pilot randomized controlled trial. [2022]
Projected long-term outcomes in patients with type 1 diabetes treated with fast-acting insulin aspart vs conventional insulin aspart in the UK setting. [2022]
The effect of insulin analogs in people with type 1 diabetes at increased risk of severe hypoglycemia. [2023]
Participatory surveillance of diabetes device safety: a social media-based complement to traditional FDA reporting. [2021]
Effect of Mini-Dose Ready-to-Use Liquid Glucagon on Preventing Exercise-Associated Hypoglycemia in Adults With Type 1 Diabetes. [2023]
Severe hypoglycaemia in adults with insulin-treated diabetes: impact on healthcare resources. [2021]
Differences in rates of hypoglycemia and health care costs in patients treated with insulin aspart in pens versus vials. [2013]
11.United Statespubmed.ncbi.nlm.nih.gov
Testing for rewards: a pilot study to improve type 1 diabetes management in adolescents. [2022]
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Back to top
Terms of Service·Privacy Policy·Cookies·Security